CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development

Ciulla, Thomas A., Hussain, Rehan M., Berrocal, Audina M., Nagiel, Aaron · 2020 · Expert Opinion on Biological Therapy

Abstract

Introduction: Over a decade of research and development culminated in the 2017 United States (US) Food and Drug Administration (FDA) approval of voretigene neparvovec-rzyl (VN) for RPE65 mutation-associated inherited retinal disease (IRD), the first approved gene therapy for a hereditary genetic disease in the US, and the first and only pharmacologic treatment for an IRD.Areas covered: VN serves as a model for ocular gene therapy development, while RPE65 mutation-associated IRD serves as an example of a well-suited candidate disorder. This review also discusses development considerations for viral vector gene augmentation, and, studies that led to VN’s FDA approval. Subretinal injection of VN resulted in improved performance on the novel multi-luminance mobility test (MLMT), light sensitivity, and visual fields in patients with RPE65 mutation-associated IRD, which predominantly impairs rod function. Additionally, the dosage, administration technique, pharmacokinetics, and safety data of VN are reviewed.Expert Opinion: As a model for development, special challenges associated with the introduction of this first ocular gene therapy include limited genetic testing in clinical practice, novel surgical complexity of ocular gene therapy administration, new functional vision endpoints, as well as unique development, launch, and reimbursement considerations associated with orphan therapies and one-time gene therapies.

Overview

Integrity signals

Registry

Crossref · 10.1080/14712598.2020.1740676

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Research works printed but not linked: 11

  1. Wenkel H, 1998, Invest Ophthalmol Vis Sci, 39, 1823
  2. Chung DC, 2018, Am J Ophthalmol
  3. Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
  4. Carter PJ, 2000, Int J Mol Med, 6, 17
  5. United States Secturities and Exchange Commission, Form 10-Q, For the quarterly period ended September 30, 2018, spark therapeutics; 2018.
  6. Drack AV, 2019, JAAPOS, 23, e7
  7. Li Q, 2008, Mol Vis, 14, 1760
  8. Yiu G, 2020, Mol Ther, 16
  9. Mahajan VB, 2018, American academy of ophthalmology
  10. Yang U, 2019, JAMA Ophthalmol, 1
  11. Brown GC, 2005, Trans Am Ophthalmol Soc, 103, 173

Cited by

See all 63

Metadata

Authors
Ciulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A.
Affiliations
  • Midwest Eye Institute (US)
  • Retina Associates Ltd, Elmhurst, IL, USA
  • University of Miami (US)
  • University of Southern California (US)
Corresponding author
Ciulla, Thomas A.
Venue
Expert Opinion on Biological Therapy
Published
2020-03-25
Volume
20
Issue
6
Pages
565-578
ISSN
  • 1471-2598 (ISSN-L)
  • 1744-7682
OpenAlex
W3009064404
Cited by
59
References
57
Citations by year
2026: 6 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 18 · 2020: 5
FWCI
3.24
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Biological Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
RPE65 mutations, inherited retinal disease, ocular gene therapy, adeno-associated virus vectors, subretinal injection, rod photoreceptor function, visual field, pharmacokinetics, gene therapy safety, FDA approval
MeSH terms
Retinoid Isomerohydrolase, Dependovirus, Clinical Trials as Topic, Conjunctival Diseases, Dose-Response Relationship, Drug, Genetic Vectors, Humans, Retinal Diseases, Tears, Genetic Therapy, cis-trans-Isomerases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development. https://app.cochat.ai/papers/10.1080/14712598.2020.1740676
The paper
Ciulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020). Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1740676

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.